Science

Yan Leyfman

Apr 4, 2025, 10:24

Yan Leyfman: InflaMix predicts CAR-T failure in Non-Hodgkin Lymphoma patients

Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Sandeep S. Raj, et al. on X:

“A study led by Dr. Roni Shouval of Memorial Sloan Kettering Cancer Center introduces InflaMix, a novel AI-driven model that predicts CAR-T failure in non-Hodgkin lymphoma (NHL) patients.

How it works: InflaMix integrates 14 lab & cytokine markers to detect inflammation and organ function before CAR-T therapy.

Key Findings:

Identified an inflammatory signature linked to higher relapse & mortality risk (HR: 2.98, P < 0.001).
Validated in 3 independent cohorts (688 NHL patients).
Outperformed standard prognostic markers, including tumor burden.
Works even with limited lab data (only 6 markers needed!).

Why it matters: InflaMix could help clinicians personalize treatment and improve patient outcomes with point-of-care decision-making.”

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.

Authors: Sandeep S. Raj, et al.

Yan Leyfman: InflaMix predicts CAR-T failure in Non-Hodgkin Lymphoma patients

cancer CAR-T therapy fight against cancer Global fight against cancer InflaMix MedNews Week Memorial Sloan Kettering Cancer Center NHL Non Hodgkin lymphoma OncoDaily Oncology Roni Shouval Sandeep S. Raj Yan Leyfman

OncoBillionaires of 2025: The Titans Behind the Cancer Revolution

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer